<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of chorea</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of chorea</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of chorea</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Oksana Suchowersky, MD, FRCPC, FCCMG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Manon Bouchard, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard I Hurtig, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 27, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H29672523"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The word "chorea" is derived from the Latin "choreus," meaning "dance." Chorea is a hyperkinetic movement disorder characterized by involuntary brief, random, and irregular contractions conveying a feeling of restlessness to the observer [<a href="#rid1">1</a>]. Chorea may be caused by hereditary neurodegenerative diseases, follow structural damage to deep brain structures, or be associated with autoimmune disorders, metabolic derangement, or certain drugs and hormones. Investigation is oriented at searching for a secondary or reversible cause of chorea or confirming a hereditary condition with genetic testing. Although the chorea arriving from acquired conditions may be reversed, there is usually no specific therapy for hereditary neurodegenerative disorders. Symptomatic treatment can reduce abnormal movements regardless of the cause.</p><p>This topic will provide an overview of the various types of chorea.</p><p class="headingAnchor" id="H29672540"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>Chorea, athetosis, and ballism frequently coexist in the same patient and are felt to be part of the same choreiform spectrum [<a href="#rid2">2,3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chorea</strong> is a hyperkinetic movement disorder characterized by rapid and unpredictable contractions affecting mostly distal limbs, but also the face and trunk. The movements are involuntary and nonpatterned with variable speed, timing, and direction, flowing from one body part to another and giving, in less severe cases, an appearance of fidgetiness. The randomness and flowing quality of chorea is a feature that distinguishes it from tremor and dystonia [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Athetosis</strong> refers to slower, writhing movements with a sinuous quality, usually affecting distal extremities or the face. The term "choreoathetosis" is used when typical choreic movements coexist with athetosis. It has been suggested that athetosis could be a manifestation of associated dystonia rather than a simple variant of chorea, such as seen in cerebral palsy [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ballism</strong> refers to involuntary movements that are proximal and large amplitude (in contrast to distal, low-amplitude contractions typical of chorea) with a flinging or kicking character. Ballism is most often unilateral (hemiballism) and although present at rest, it becomes more prominent with action [<a href="#rid5">5</a>].</p><p></p><p class="headingAnchor" id="H29672548"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The structures involved in the production of chorea are the caudate nucleus, putamen, subthalamic nucleus, thalamus, and their interconnecting pathways [<a href="#rid1">1,6</a>]. Chorea results from damage or dysfunction of these structures that causes an imbalance between indirect and direct pathways in the basal ganglia circuitry, leading to excessive dopaminergic activity. Disruption of the indirect pathway with loss of inhibition to the pallidum allows hyperkinetic movements to occur [<a href="#rid1">1</a>]. The disruption of basal ganglia circuitry may be due to structural damage, selective neuronal degeneration, neurotransmitter receptor blockade, metabolic derangements, or autoimmune conditions.</p><p class="headingAnchor" id="H29672556"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The prevalence of choreas as a whole is unknown since there are no community-based studies available. Huntington disease (HD) is the most frequent cause of hereditary chorea, with a worldwide prevalence rate of approximately 3 per 100,000 (see  <a class="medical medical_review" href="/d/html/4907.html" rel="external">"Huntington disease: Clinical features and diagnosis", section on 'Epidemiology'</a>). Although much rarer, this is followed by <em>C9ORF72 </em>gene mutations and HDL4/SCA17.</p><p>The most common cause of acquired chorea in adults is likely levodopa-induced dyskinesia. In an Italian series of 51 consecutive cases of chorea admitted to several neurology departments over a five-year period, the most frequent etiologies of chorea were vascular (40 percent), drug induced (14 percent), HD (10 percent), and acquired immune deficiency syndrome (10 percent) [<a href="#rid7">7</a>]. Other causes were found in less than 5 percent of patients, and the diagnosis remained unknown in 6 percent.</p><p>In children, Sydenham chorea (SC) accounts for up to 96 percent of acute chorea cases [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/6228.html" rel="external">"Sydenham chorea"</a>.)</p><p class="headingAnchor" id="H29672564"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Chorea is usually classified as being primary (idiopathic, hereditary) or secondary (acquired).</p><p>Hereditary choreas  (<a class="graphic graphic_table graphicRef95649" href="/d/graphic/95649.html" rel="external">table 1</a>) tend to develop insidiously (over more than one year) and are generally symmetrical, whereas acquired choreas  (<a class="graphic graphic_table graphicRef95650" href="/d/graphic/95650.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef95651" href="/d/graphic/95651.html" rel="external">table 3</a>) are more likely to be acute or subacute and can be asymmetrical or unilateral. Therefore, choreas could also be divided according to their mode of onset (acute or insidious) or their distribution (unilateral or bilateral). In any case of unilateral chorea, a focal lesion should be sought, although the etiology is often linked to a systemic disorder. Age of onset can also be used to classify choreas. In children, most cases of chorea are acquired and develop acutely or subacutely, the most common etiology being Sydenham chorea (SC).</p><p class="headingAnchor" id="H29672572"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Chorea usually affects the distal limbs and face, but may also interfere with respiration and phonation, resulting in slurred speech or involuntary vocalizations [<a href="#rid5">5</a>]. The continuous flow of movements may appear semi-purposeful and difficult to distinguish from restless or fidgety behavior. Moreover, patients may mask the chorea by incorporating choreic movements into voluntary movements (parakinesia) [<a href="#rid3">3,5</a>]. Patients are often unaware of their abnormal movements, which are noted by family members.</p><p>Chorea is usually present at rest and may increase with distracting maneuvers, but disappears in sleep [<a href="#rid5">5</a>]. Patients with chorea often demonstrate motor impersistence, an inability to maintain an ongoing motor activity, such as holding the tongue out or maintaining a constant grip [<a href="#rid5">5</a>].</p><p>Chorea has the same phenomenology regardless of its etiology. Hence, the differential diagnosis relies on accompanying features, age, and mode of onset [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H29672584"><span class="h1">HEREDITARY CAUSES OF CHOREA</span><span class="headingEndMark"> — </span>There are many different causes of hereditary chorea  (<a class="graphic graphic_table graphicRef95649" href="/d/graphic/95649.html" rel="external">table 1</a>). Patterns of inheritance include autosomal dominant, autosomal recessive, and X-linked, as reviewed in the sections that follow.</p><p class="headingAnchor" id="H29672591"><span class="h2">Autosomal dominant</span><span class="headingEndMark"> — </span>Important autosomal-dominant causes of hereditary chorea include Huntington disease (HD), <em>C9ORF72</em> repeat expansions, Huntington disease-like (HDL) syndromes, benign hereditary chorea, dentatorubral pallidoluysian atrophy (DRPLA), several types of spinocerebellar ataxia (SCA), and neuroferritinopathy.</p><p class="headingAnchor" id="H29672598"><span class="h3">Huntington disease</span><span class="headingEndMark"> — </span>HD is by far the most common cause of hereditary chorea. HD is caused by a cytosine-adenine-guanine (CAG) trinucleotide repeat expansion of the huntingtin (<em>HTT</em>) gene on chromosome 4p leading to an enlarged polyglutamine tract in the huntingtin protein. This protein is widely expressed in the human brain, but its exact function is unknown. In HD, neuronal loss occurs predominantly in the caudate and putamen. (See  <a class="medical medical_review" href="/d/html/6182.html" rel="external">"Huntington disease: Genetics and pathogenesis"</a>.)</p><p>Clinically, adult-onset HD is characterized by insidious development of chorea, cognitive decline, and behavioral changes leading to relentlessly increasing disability and ultimately death  (<a class="graphic graphic_table graphicRef57709" href="/d/graphic/57709.html" rel="external">table 4</a>). The first symptoms typically occur at ages 30 to 50 years, but age of onset varies from childhood to the 80s. Chorea is a key feature of HD in adults, and the defining sign at the time of diagnosis. (See  <a class="medical medical_review" href="/d/html/4907.html" rel="external">"Huntington disease: Clinical features and diagnosis"</a>.)</p><p>Onset of symptoms before 20 years of age is considered juvenile HD. The clinical presentation of juvenile HD is different from adults, and is marked by a combination of parkinsonism, dystonia, and myoclonus without prominent chorea  (<a class="graphic graphic_table graphicRef61297" href="/d/graphic/61297.html" rel="external">table 5</a>). Seizures are also common. Most have the akinetic-rigid syndrome termed the "Westphal variant." Juvenile HD has a more rapid course with early dementia. (See  <a class="medical medical_review" href="/d/html/6231.html" rel="external">"Bradykinetic movement disorders in children", section on 'Juvenile Huntington disease'</a>.)</p><p>No treatment for HD has yet been shown to slow the progression or delay the onset of the disease. Innovative genetic therapies are under active investigation. Symptomatic treatment is offered for chorea and behavioral or cognitive symptoms as needed. (See  <a class="medical medical_review" href="/d/html/4902.html" rel="external">"Huntington disease: Management"</a>.)</p><p class="headingAnchor" id="H56514472"><span class="h3">C9ORF72 repeat expansions</span><span class="headingEndMark"> — </span>Neurodegenerative disease caused by hexanucleotide repeat expansions in the <em>C9ORF72</em> gene can present as an HD phenocopy. In a cohort of 514 patients with suspected HD in whom genetic testing for <em>HTT</em> was negative, repeat expansions in the <em>C9ORF72</em> gene were identified in 10 patients (2 percent), making it the most common genetic cause of HD phenocopy syndromes [<a href="#rid9">9</a>]. In addition to chorea, patients can present with dystonia, ataxia, parkinsonism, myoclonus, and pyramidal signs [<a href="#rid9">9</a>].</p><p>Limited available data suggest autosomal dominant transmission with incomplete penetrance. Mutations in the <em>C9ORF</em> gene involving the repeat expansion are the most common cause of familial frontotemporal dementia (FTD) and familial amyotrophic lateral sclerosis (ALS), and have been identified in some sporadic cases of FTD, ALS, and parkinsonism. (See  <a class="medical medical_review" href="/d/html/5176.html" rel="external">"Familial amyotrophic lateral sclerosis", section on 'C9ORF72 gene'</a> and  <a class="medical medical_review" href="/d/html/5156.html" rel="external">"Epidemiology and pathogenesis of amyotrophic lateral sclerosis", section on 'Genetic susceptibility in sporadic ALS'</a> and  <a class="medical medical_review" href="/d/html/14138.html" rel="external">"Frontotemporal dementia: Epidemiology, pathology, and pathogenesis", section on 'C9orf72 expansion'</a>.)</p><p class="headingAnchor" id="H29672615"><span class="h3">Huntington disease-like syndromes</span><span class="headingEndMark"> — </span>The HDL syndromes, numbered 1 through 4, are rare causes of chorea and can present as HD mimics with a combination of chorea, personality changes, and dementia [<a href="#rid10">10,11</a>]. Except for HDL3, they are autosomal dominant and the onset is usually between 20 and 45 years of age.</p><p class="bulletIndent1"><span class="glyph">●</span>HDL1 typically presents like HD, but seizures have also been described [<a href="#rid12">12</a>]. It is caused by octapeptide repeat insertions in the <em>PRNP</em> gene on chromosome 20, encoding the prion protein [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HDL2 is usually found in families of African ancestry and is more common than HD in Black South Africans [<a href="#rid11">11,13</a>]. However, it has also been described in patients of European and Middle Eastern ancestry [<a href="#rid14">14,15</a>]. HDL2 is caused by a CAG/cytosine-thymine-guanine (CTG) triplet expansion in the <em>JPH3</em> gene encoding junctophilin-3, a protein of unknown function [<a href="#rid10">10,13</a>]. Acanthocytes can sometimes be found in the peripheral blood smear [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/d/html/14122.html" rel="external">"Neuroacanthocytosis", section on 'Huntington disease-like 2'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HDL3 is autosomal recessive and has only been described in two families from Saudi Arabia [<a href="#rid11">11</a>]. The disease appears in early childhood and is characterized by a combination of chorea, dystonia, ataxia, gait instability, spasticity, seizures, mutism, and intellectual impairment [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HDL4, better known as SCA17, has a markedly heterogeneous phenotype. The typical presentation includes cerebellar ataxia (the most common feature), intellectual decline, and epilepsy, but some patients can present with chorea [<a href="#rid10">10,19</a>]. Affected individuals can also exhibit dystonia, parkinsonism, pyramidal signs, epilepsy, dementia, and behavioral disturbances [<a href="#rid10">10,20</a>]. HDL4/SCA17 is caused by a CAG/cytosine-adenine-adenine (CAA) expansion in the <em>TBP</em> gene encoding TATA-box binding protein. (See  <a class="medical medical_review" href="/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias", section on 'SCA types 9 to 20'</a>.)</p><p></p><p class="headingAnchor" id="H29672623"><span class="h3">Benign hereditary chorea</span><span class="headingEndMark"> — </span>Benign hereditary chorea is classically associated with autosomal dominant mutations in the <em>NKX2-1</em> gene (also known as the <em>TITF1</em> gene) on chromosome 14q. Patients usually present in infancy with mild, nonprogressive chorea and hypotonia. Chorea can even improve with age. Despite its name, this disorder is not always benign. Many patients also exhibit educational or behavioral difficulties, delayed motor milestones, dysarthria, axial dystonia, gait disturbance, tics, tremor, or myoclonic jerks [<a href="#rid4">4,21</a>]. (See  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Childhood-onset hereditary chorea'</a>.)</p><p>Since the <em>NKX2-1</em> gene is also responsible for lung and thyroid development, involvement of these organs often coexists and can be a diagnostic clue, hence the term "brain-lung-thyroid syndrome." Mutations in the <em>MBIP </em>gene, which is located upstream from the <em>NKX2-1</em> gene, have also been reported in association with the same symptoms. Both <em>NKX2-1</em> and <em>MBIP</em> can be associated with an increased risk of malignancy [<a href="#rid22">22</a>].</p><p>Phenotypes similar to <em>NKX2-1</em> gene-related benign hereditary chorea have been described with mutations in other genes, including <em>ADCY5</em>, <em>PDE10A</em>, <em>GNAO1</em>, and <em>SLC16A2</em>, although all have additional features to chorea [<a href="#rid4">4,23</a>]. (See <a class="local">'ADCY5 and PDE10A mutations'</a> below.)</p><p class="headingAnchor" id="H29672631"><span class="h3">Dentatorubral pallidoluysian atrophy</span><span class="headingEndMark"> — </span>DRPLA is a rare disorder caused by CAG triplet expansions in the <em>ATN1</em> gene encoding atrophin-1. The expansion can result in anticipation with paternal transmission. DRPLA is particularly prevalent in Japan, but has been reported in other ethnic groups as well. The age of onset varies widely. In adults, DRPLA causes ataxia, choreoathetosis, and cognitive decline and can mimic HD. A distinctive feature is myoclonic epilepsy, which is common in juvenile-onset cases. (See  <a class="medical medical_review" href="/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias", section on 'Dentatorubral pallidoluysian atrophy'</a>.)</p><p class="headingAnchor" id="H29672639"><span class="h3">Spinocerebellar ataxias</span><span class="headingEndMark"> — </span>The SCAs are a group of heterogeneous disorders  (<a class="graphic graphic_table graphicRef74269" href="/d/graphic/74269.html" rel="external">table 6</a>) characterized by progressive cerebellar ataxia often associated with other neurologic signs such as ophthalmoplegia, pyramidal or extrapyramidal signs, deep sensory loss, and dementia. Onset can be in childhood or old age, but is generally between 20 to 40 years. SCA types 1, 2, 3, and 17 are more likely than other SCA types to cause chorea [<a href="#rid1">1,19</a>]. (See  <a class="medical medical_review" href="/d/html/6230.html" rel="external">"Autosomal dominant spinocerebellar ataxias"</a>.)</p><p class="headingAnchor" id="H29672647"><span class="h3">Neuroferritinopathy</span><span class="headingEndMark"> — </span>Neuroferritinopathy is a form of neurodegeneration with brain iron accumulation (NBIA), a rare progressive syndrome that causes parkinsonism, dystonia, cognitive decline, and other neurologic deficits. NBIA is made up of several phenotypically overlapping disorders, with subtypes defined by differences at the molecular genetic level. (See  <a class="medical medical_review" href="/d/html/6231.html" rel="external">"Bradykinetic movement disorders in children", section on 'Neurodegeneration with brain iron accumulation'</a>.)</p><p>Neuroferritinopathy results in accumulation of iron in basal ganglia due to a mutation in the <em>FTL</em> gene encoding the ferritin light chain. It is characterized by adult onset of extrapyramidal features like chorea, dystonia, or parkinsonism that are commonly asymmetrical and associated with cognitive impairment [<a href="#rid10">10,19,24</a>]. Action-specific facial dystonia is particularly typical [<a href="#rid25">25</a>]. Dysarthria, spasticity, and cerebellar signs can also be seen [<a href="#rid26">26,27</a>]. Blood work shows low serum ferritin and brain magnetic resonance imaging (MRI) invariably reveals abnormal deposition of iron in the basal ganglia with gradient echo (T2*) signal loss, as well as cystic changes and necrosis in basal ganglia [<a href="#rid24">24,27,28</a>]. A distinct imaging pattern of iron deposition, termed "pencil lining," has been observed on susceptibility-weighted MRI with linear areas of low signal that outline the cerebral and cerebellar cortices and other gray matter structures as if traced by a black pencil [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H2856517418"><span class="h3">ADCY5 and PDE10A mutations</span><span class="headingEndMark"> — </span>Autosomal dominant mutations in the <em>ADCY5</em> gene have been reported to cause a broad range of childhood-onset hyperkinetic movement disorders, sometimes referred to as familial dyskinesia with facial myokymia. Although chorea is often the main feature, patients can exhibit facial myokymias, dystonia, and myoclonus [<a href="#rid24">24</a>]. Clinical features that should raise suspicion for an <em>ADCY5</em> mutation are onset of symptoms in the first years of life, absence of cognitive involvement, prominent facial twitches, and marked fluctuations of symptoms, either as paroxysmal attacks or exacerbations at night or upon awakening [<a href="#rid30">30</a>]. Some patients may experience episodic attacks before the movement disorder becomes persistent [<a href="#rid31">31</a>].</p><p>Childhood-onset chorea has also been associated with dominant or recessive mutations in the <em>PDE10A</em> gene [<a href="#rid32">32</a>]. Patients have hyperintense bilateral striatal lesions on brain MRI [<a href="#rid30">30,32</a>].</p><p class="headingAnchor" id="H29672664"><span class="h2">Autosomal recessive</span><span class="headingEndMark"> — </span>Important autosomal recessive causes of hereditary chorea include chorea-acanthocytosis, Wilson disease, pantothenate kinase-associated neurodegeneration (PKAN), ataxia-telangiectasia, and ataxia with oculomotor apraxia (AOA).</p><p class="headingAnchor" id="H29672671"><span class="h3">Chorea-acanthocytosis</span><span class="headingEndMark"> — </span>The clinical manifestations of chorea-acanthocytosis (also called choreoacanthocytosis) include chorea, dystonia, tics, parkinsonism, eye movement abnormalities, behavioral changes, and cognitive decline. The phenotype can be similar to HD, although orofacial and lingual dyskinesia are typically prominent and troublesome, resulting in self-mutilating lip and tongue biting and difficulty swallowing. Seizures, peripheral neuropathy with distal amyotrophy, and elevated serum creatine kinase are common. The mean age of onset is 30 years, and the disease is relentlessly progressive, with death occurring within 15 years of onset. Acanthocytes are usually present on peripheral blood films, but their absence does not exclude the diagnosis. Chorea-acanthocytosis is caused by a mutation in the <em>VPS13A</em> gene on chromosome 9, which encodes for the protein chorein. (See  <a class="medical medical_review" href="/d/html/14122.html" rel="external">"Neuroacanthocytosis", section on 'Chorea-acanthocytosis'</a>.)</p><p class="headingAnchor" id="H29672679"><span class="h3">Wilson disease</span><span class="headingEndMark"> — </span>Chorea is a rare symptom of Wilson disease, but this condition should not be missed, because it is a treatable disorder. Wilson disease should be considered in all patients with a movement disorder who are under 40 years of age. (See  <a class="medical medical_review" href="/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history"</a>.)</p><p>Wilson disease is a disorder of copper excretion caused by a mutation in the <em>ATP7B</em> gene resulting in relentless multisystemic copper accumulation. (See  <a class="medical medical_review" href="/d/html/3626.html" rel="external">"Wilson disease: Epidemiology and pathogenesis"</a>.)</p><p>The clinical phenotype of Wilson disease is broad. The majority of patients with Wilson disease are diagnosed between the ages of 5 and 35 years, though it has been diagnosed in younger patients and in patients in their 70s. Unlike children, who are more likely to present with hepatic manifestations, older patients (mid-teens and older) are more likely to present with neurologic manifestations. Common neurologic manifestations of Wilson disease include tremor, dysarthria, ataxia, dystonia, parkinsonism, and drooling. Other symptoms can include risus sardonicus, tics, myoclonus, chorea, whispering dysphonia, seizures, and behavioral and cognitive changes. Nearly all patients with neurologic symptoms will exhibit Kayser-Fleisher rings  (<a class="graphic graphic_picture graphicRef65925" href="/d/graphic/65925.html" rel="external">picture 1</a>) on careful slit lamp examination. These rings are gold, brown, or greenish and first become visible in the upper pole of peripheral cornea. Investigation demonstrates low ceruloplasmin levels in most patients (normal in 5 to 15 percent of cases), low serum copper levels, increased 24-hour urine copper excretion, and abnormal liver function tests. Liver biopsy or genetic testing can confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/83837.html" rel="external">"Wilson disease: Clinical manifestations, diagnosis, and natural history"</a>.)</p><p>Brain MRI is nearly always abnormal in neurologic Wilson disease, showing hyperintensities in basal ganglia or claustrum on T2-weighted images or signal abnormalities in the midbrain ("face of the giant panda").</p><p class="headingAnchor" id="H29672687"><span class="h3">Pantothenate kinase-associated neurodegeneration</span><span class="headingEndMark"> — </span>PKAN, formerly known as Hallervorden-Spatz disease, is another subtype of NBIA. (See  <a class="medical medical_review" href="/d/html/6231.html" rel="external">"Bradykinetic movement disorders in children", section on 'Neurodegeneration with brain iron accumulation'</a>.)</p><p>PKAN is caused by mutations in the gene encoding pantothenate kinase 2 (<em>PANK2</em>) and results in accumulation of iron in the basal ganglia, most abundant in globus pallidus interna. Onset is in the first decade, typically with gait dystonia evolving into generalized dystonia, dysarthria, parkinsonism, spasticity, pigmentary retinal degeneration, dementia, and behavioral changes. Brain MRI is invariably abnormal, typically showing the characteristic radiologic sign known as "eye of the tiger" with a central focus of increased T2 signal intensity in the medial globus pallidus surrounded by a zone of decreased signal. (See  <a class="medical medical_review" href="/d/html/6231.html" rel="external">"Bradykinetic movement disorders in children", section on 'Neurodegeneration with brain iron accumulation'</a>.)</p><p class="headingAnchor" id="H29672695"><span class="h3">Ataxia-telangiectasia</span><span class="headingEndMark"> — </span>Ataxia-telangiectasia is the next most common autosomal recessive ataxia after Friedreich ataxia, with an estimated incidence of 1 in 20,000 to 100,000 live births. It is caused by mutations in the ataxia telangiectasia mutated (<em>ATM</em>) gene on chromosome 11; the <em>ATM</em> gene product is involved in the detection of DNA damage. The disease onset is usually between one to four years of age with progressive cerebellar ataxia. Over time, associated features become evident: conjunctival or facial telangiectasias, oculomotor apraxia, chorea, dystonia, myoclonus, and peripheral neuropathy. Associated features include immunodeficiency with recurrent sinus or pulmonary infections, an increased incidence of malignancy, radiation sensitivity, and diabetes mellitus caused by insulin resistance. The diagnosis is established by the presence of characteristic clinical findings (particularly progressive cerebellar ataxia) and identification of pathogenic variants on both alleles for the <em>ATM</em> gene. It is supported by serum immunoglobulin A at least two standard deviations below normal for age and by increased spontaneous and radiation-induced chromosome fragility in cultured cells. In the appropriate clinical setting, the finding of a serum alpha-fetoprotein at least two standard deviations above normal for age is diagnostic of the disorder. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia"</a>.)</p><p class="headingAnchor" id="H29672703"><span class="h3">Ataxia with oculomotor apraxia</span><span class="headingEndMark"> — </span>AOA types 1 (AOA1) and 2 (AOA2; also called ataxia-ocular apraxia types 1 and 2) are disorders that present as autosomal recessive or sporadic cerebellar ataxias with oculomotor apraxia, chorea, facial and limb dystonias, sensorimotor polyneuropathy, and cognitive impairment.</p><p>AOA1, also known as early-onset AOA, usually presents in the first decade of life, although onset has been reported as late as age 25 years. It is associated with hypercholesterolemia and hypoalbuminemia. The disease is caused by mutations of the <em>APTX</em> gene coding for aprataxin, a protein involved in single-strand DNA repair. Most reported cases are of Portuguese, Italian, and Japanese descent. (See  <a class="medical medical_review" href="/d/html/6233.html" rel="external">"Ataxia-telangiectasia", section on 'Differential diagnosis'</a>.)</p><p>AOA2 is similar to AOA1 but is more common and has a later age of onset (from 20 to 60 years) and slower progression. It is less frequently associated with cognitive impairment, and oculomotor apraxia is a feature in only approximately 50 percent of cases. Patients usually have elevated alpha-fetoprotein and creatine kinase. The disease results from mutations in the <em>SETX</em> gene that encodes senataxin, a protein also involved in single-strand DNA repair.</p><p class="headingAnchor" id="H29672711"><span class="h2">X-linked</span><span class="headingEndMark"> — </span>The main X-linked causes of chorea include McLeod syndrome and Lesch-Nyhan syndrome.</p><p class="headingAnchor" id="H29672718"><span class="h3">McLeod syndrome</span><span class="headingEndMark"> — </span>The phenotype of McLeod syndrome is similar to chorea-acanthocytosis, with a combination of chorea, subcortical cognitive deficits, behavioral changes, peripheral axonal polyneuropathy, myopathy (usually mild or subclinical) with elevated creatine kinase, and possible seizures (in approximately one-half of patients). However, this disease begins later, between 20 and 50 years, and lacks the self-mutilation or eating difficulties typical of chorea-acanthocytosis. Associated features include cardiac involvement with cardiomyopathy and arrhythmias in approximately two-thirds. Acanthocytes are seen on peripheral blood smear. McLeod syndrome is due to a mutation on the <em>XK</em> gene causing reduction of all Kell antigens and absence of Kx antigen on red blood cells. (See  <a class="medical medical_review" href="/d/html/14122.html" rel="external">"Neuroacanthocytosis", section on 'Mcleod syndrome'</a>.)</p><p class="headingAnchor" id="H50201562"><span class="h3">Lesch-Nyhan syndrome</span><span class="headingEndMark"> — </span>Lesch-Nyhan syndrome is a complex motor-behavioral condition that is inherited as an X-linked recessive trait. The disorder results from mutations in the gene coding for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT), leading to deficient enzyme activity. This defect results in an often marked increase in production of uric acid and hyperuricemia. The wide spectrum of neurologic symptoms (with some patients being asymptomatic) and severity of the disease have been associated with the degree of enzyme deficiency. Affected boys have delayed developmental milestones, intellectual disability, and extrapyramidal and pyramidal motor symptoms; they also develop self-mutilating behavior. While earlier literature emphasized choreoathetosis and spasticity as typical features of the motor disorder associated with Lesch-Nyhan syndrome, dystonia is more common. (See  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Lesch-Nyhan syndrome'</a>.)</p><p class="headingAnchor" id="H29672726"><span class="h1">ACQUIRED CAUSES OF CHOREA</span><span class="headingEndMark"> — </span>A variety of acquired conditions can cause chorea  (<a class="graphic graphic_table graphicRef95650" href="/d/graphic/95650.html" rel="external">table 2</a>). These include central nervous system vascular lesions; autoimmune/inflammatory disorders, particularly Sydenham chorea (SC); metabolic and endocrine disorders; infectious diseases; toxins; drugs  (<a class="graphic graphic_table graphicRef95651" href="/d/graphic/95651.html" rel="external">table 3</a>); structural lesions of the basal ganglia; and so-called senile chorea.</p><p class="headingAnchor" id="H69778522"><span class="h2">Vascular</span><span class="headingEndMark"> — </span>Chorea can occur as a consequence of acute ischemic or hemorrhagic stroke or in the context of low-grade ischemic changes in the basal ganglia without obvious infarction. Ischemic and hemorrhagic stroke are the most common causes of nongenetic chorea in the hospital population. Stroke results in early or delayed contralateral hemichorea or hemiballism in less than 1 percent of patients [<a href="#rid33">33-35</a>].</p><p>In contrast to traditional textbook concepts, a lesion of the subthalamic nucleus is found in only a minority of cases of vascular hemichorea/hemiballism. Other reported localizations include the caudate nucleus, putamen, thalamus, globus pallidus, corona radiata, subcortical white matter, and cortex [<a href="#rid35">35-37</a>]. Despite this anatomic heterogeneity, there is evidence that most stroke lesions causing hemichorea/hemiballism involve a common functional network connected to the posterolateral putamen [<a href="#rid38">38</a>]. The majority of patients improve within one or two years, but chorea will persist in some individuals [<a href="#rid35">35,37</a>].</p><p>Moyamoya disease can rarely present with movement disorders such as unilateral or bilateral acute or subacute chorea and paroxysmal dyskinesia, especially in children. (See  <a class="medical medical_review" href="/d/html/1131.html" rel="external">"Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis", section on 'Clinical presentations'</a>.)</p><p>Post-pump chorea, also known as postoperative encephalopathy with choreoathetosis, is a rare form of chorea following extracorporeal circulation. It is typically seen in children, but it can also occur in adult patients [<a href="#rid39">39</a>]. It is possibly caused by hypoxia, hypothermia, or a combination of both. Some patients are left with persistent abnormal movements and cognitive and behavioral changes. (See  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Post-pump chorea'</a>.)</p><p>Chorea rarely occurs in polycythemia vera (0.5 to 5 percent of patients), especially in older women, and can precede hematologic changes [<a href="#rid40">40</a>]. The choreic syndrome is usually acute and generalized with predominant involvement of the orofaciolingual muscles, but it may be unilateral. (See  <a class="medical medical_review" href="/d/html/4517.html" rel="external">"Clinical manifestations and diagnosis of polycythemia vera"</a>.)</p><p class="headingAnchor" id="H29672733"><span class="h2">Autoimmune or inflammatory disorders</span><span class="headingEndMark"> — </span>SC is a common cause of chorea in children. Rare autoimmune or inflammatory causes of chorea include paraneoplastic chorea, systemic lupus erythematosus (SLE), and several other immune-mediated conditions [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H29672740"><span class="h3">Sydenham chorea</span><span class="headingEndMark"> — </span>SC is the most common cause of chorea in childhood. It is one of the clinical manifestations of acute rheumatic fever, a nonsuppurative sequela of group A streptococcus infection. SC is an autoimmune disorder, thought to result from cross-reactivity between antibodies to group A streptococcal bacteria and striatal antigens. (See  <a class="medical medical_review" href="/d/html/6228.html" rel="external">"Sydenham chorea", section on 'Pathophysiology'</a>.)</p><p>SC typically occurs in children between 5 and 15 years, although it has also been described in adults. Females are affected more frequently than males by a ratio of 2:1. As opposed to the other major manifestations (ie, arthritis, carditis, erythema marginatum, subcutaneous nodules) of acute rheumatic fever, which emerge one to three weeks after the inciting infection, SC is a later manifestation occurring commonly four to eight weeks after the infection, although it can be delayed up to eight months. Chorea develops subacutely and is generally bilateral, but 20 to 30 percent of cases will experience hemichorea. Affected patients can also exhibit tics, dysarthria, hypotonia, muscular weakness, gait disorder, and vocalizations. SC is often associated with psychologic and psychiatric manifestations that may precede the onset of chorea, including emotional lability with irritability, inattention, hyperactivity, obsessive compulsiveness, anxiety, psychotic symptoms, and depression. The bouts of chorea typically last two to nine months followed by complete spontaneous resolution. However, a substantial proportion of patients has persistence of chorea after two years or has recurrences. Individuals who have developed SC are at increased risk of developing chorea associated with subsequent group A beta-hemolytic streptococcus (GABHS) pharyngitis, pregnancy, oral contraceptives, or other drugs. (See  <a class="medical medical_review" href="/d/html/6228.html" rel="external">"Sydenham chorea", section on 'Clinical manifestations'</a>.)</p><p>The diagnosis of SC is made clinically, based on characteristic neurologic findings. Some patients with SC have no other manifestations of acute rheumatic fever but should have an evaluation for carditis with echocardiography. Since SC is a late manifestation of the streptococcal infection, throat culture at the moment of the chorea is usually negative, and other signs of systemic inflammation have often abated. The antistreptolysin O titer is of limited use in patients with SC because titers generally peak before the onset of SC symptoms and children without rheumatic fever or SC often have low positive titers of ASLO. The antideoxyribonuclease B titer is more useful for supporting the diagnosis of SC because it tends to remain elevated longer. (See  <a class="medical medical_review" href="/d/html/6228.html" rel="external">"Sydenham chorea", section on 'Diagnostic evaluation'</a>.)</p><p>Although most patients with SC recover fully without treatment, those with significant impairment of motor function and the possibility of self-injury may benefit from treatment as discussed separately. (See  <a class="medical medical_review" href="/d/html/6228.html" rel="external">"Sydenham chorea", section on 'Treatment'</a>.)</p><p>All patients with SC should be given treatment for acute pharyngitis followed by prophylactic antibiotic therapy to prevent rheumatic recurrences, which can manifest as chorea, carditis, or psychiatric symptoms. The prophylaxis should be continued at least until early adulthood. (See  <a class="medical medical_review" href="/d/html/3175.html" rel="external">"Acute rheumatic fever: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H29672757"><span class="h3">Paraneoplastic chorea</span><span class="headingEndMark"> — </span>Chorea is a rare paraneoplastic manifestation of cancer, usually associated with CV2/collapsin-responsive mediator protein 5 (CRMP5) antibodies in the context of small cell lung carcinoma [<a href="#rid42">42,43</a>]. The majority of these patients also have other neurologic signs and symptoms, such as vision loss, neuropathy, ataxia, or limbic encephalitis [<a href="#rid44">44</a>]. Chorea has also been reported in other cancers (breast cancer, thymoma, lymphoma, renal cell carcinoma, and testicular cancer) and with other types of antibodies (anti-Hu, anti-Ri, anti-Yo) [<a href="#rid41">41,42,45-47</a>]. The majority of patients with paraneoplastic chorea show abnormal signal in basal ganglia on MRI. Chorea improves with treatment of the underlying malignancy. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'High-risk antibodies (&gt;70 percent cancer association)'</a>.)</p><p>Paraneoplastic encephalitis associated with N-methyl-D-aspartate (NMDA) receptor antibodies often presents with abnormal movements including chorea, stereotypies, dystonia, and myoclonus, and is usually associated with other neurologic signs such as behavioral or psychiatric manifestations, ataxia, and seizures [<a href="#rid48">48</a>]. NMDA encephalitis can be associated with ovarian teratoma or can be autoimmune, without an underlying tumor. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-NMDA receptor encephalitis'</a>.)</p><p>Encephalitis caused by antibodies against leucine-rich glioma inactivated 1 (LGI1), contactin-associated protein-like 2 (Caspr2), Hu, or gamma-aminobutyric acid type B (GABA-B) receptors can also feature bilateral or unilateral chorea, with either paraneoplastic or autoimmune origin [<a href="#rid48">48-50</a>]. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-LGI1 encephalitis'</a> and  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-Caspr2-associated encephalitis'</a>.)</p><p class="headingAnchor" id="H29672765"><span class="h3">Other immune-mediated choreas</span><span class="headingEndMark"> — </span>Although central nervous system involvement is common (up to 80 percent) in SLE, chorea is an uncommon manifestation [<a href="#rid51">51</a>]. Chorea is also seen in approximately 1 percent of patients with primary antiphospholipid syndrome [<a href="#rid51">51</a>]. In childhood, chorea can appear long before the other manifestations of SLE or the antiphospholipid syndrome. (See  <a class="medical medical_review" href="/d/html/4863.html" rel="external">"Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Chorea'</a> and  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Other acquired causes'</a> and  <a class="medical medical_review" href="/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome", section on 'Neurologic involvement'</a>.)</p><p>Chorea is an uncommon or rare manifestation of other immune diseases such as Behçet syndrome, Sjögren's disease, immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]), polyarteritis nodosa, primary angiitis of the central nervous system, celiac disease, and sarcoidosis [<a href="#rid3">3,52-56</a>]. (See  <a class="medical medical_review" href="/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome"</a> and  <a class="medical medical_review" href="/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease"</a> and  <a class="medical medical_review" href="/d/html/7480.html" rel="external">"Neurologic manifestations of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and  <a class="medical medical_review" href="/d/html/8230.html" rel="external">"Primary angiitis of the central nervous system in adults"</a> and  <a class="medical medical_review" href="/d/html/16367.html" rel="external">"Childhood primary angiitis of the central nervous system: Angiography-positive subtype"</a> and  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a> and  <a class="medical medical_review" href="/d/html/5899.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in children"</a> and  <a class="medical medical_review" href="/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p>Anti-IgLON5 disease is a slowly progressive disorder with a unique combination of autoimmune-mediated inflammation associated with neuropathological tau protein accumulation. Most patients experience sleep abnormalities (severe insomnia, non-rapid eye movement [REM] sleep parasomnias, REM sleep behavior disorder, obstructive sleep apnea) along with other neurologic manifestations such as chorea or other movement disorders, dementia, ataxia, dysautonomia, peripheral signs, and vertical supranuclear gaze palsy [<a href="#rid57">57</a>]. Antibodies to IgLON5 are present in both serum and cerebrospinal fluid (CSF), and most patients have partial response to immunotherapy. (See  <a class="medical medical_review" href="/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-IgLON5 disease'</a>.)</p><p class="headingAnchor" id="H29672773"><span class="h2">Metabolic and endocrine disorders</span><span class="headingEndMark"> — </span>Chorea gravidarum, hyperglycemia, and other metabolic or endocrine disorders may be associated with chorea.</p><p class="headingAnchor" id="H29672780"><span class="h3">Chorea gravidarum</span><span class="headingEndMark"> — </span>Pregnancy-induced chorea is typically unilateral and begins after the first trimester of pregnancy, to improve later in the pregnancy or after delivery [<a href="#rid58">58</a>]. Women with a previous history of chorea associated with oral contraceptive use, SC, SLE, or antiphospholipid antibody syndrome are more prone to developing chorea gravidarum. The abnormal movements may recur in subsequent pregnancies. (See  <a class="medical medical_review" href="/d/html/4838.html" rel="external">"Neurologic disorders complicating pregnancy", section on 'Chorea gravidarum'</a>.)</p><p class="headingAnchor" id="H3534590909"><span class="h3">Hyperglycemia</span><span class="headingEndMark"> — </span>Nonketotic hyperglycemic hemichorea-hemiballism (also referred to as "diabetic striatopathy") is a well-described cause of acute acquired hemichorea in adults [<a href="#rid33">33,59-61</a>]. Most cases occur in the setting of poorly controlled, longstanding type 2 diabetes (mean blood glucose 414 mg/dL, mean glycated hemoglobin 13.1 percent) [<a href="#rid61">61</a>], although this condition is also seen in newly diagnosed diabetes or acute hyperglycemia. Aside from poor glucose control, risk factors include older age and female sex [<a href="#rid36">36,62</a>].</p><p>Most patients present with acute hemichorea involving both arm and leg; facial involvement and bilateral chorea have also been described. The characteristic finding on MRI is hyperintense signal abnormality on T1-weighted images in the contralateral striatum, with normal diffusion-weighted and susceptibility images  (<a class="graphic graphic_figure graphicRef139598" href="/d/graphic/139598.html" rel="external">figure 1</a>) [<a href="#rid63">63</a>]. These characteristics distinguish striatopathy from hemorrhage, which may be initially suspected based on computed tomography (CT) showing an area of hyperdense signal in the striatum. Thus, MRI is critical to making the correct diagnosis.</p><p>Most patients show remission of chorea over a period of days to several weeks once glycemic control is achieved, but abnormal movements can persist for more than a year or recur after previous remission. Short-term use of symptomatic therapies for chorea (eg, antipsychotic drugs) may be needed for severe cases. (See <a class="local">'Management of chorea'</a> below.)</p><p class="headingAnchor" id="H3753071563"><span class="h3">Other metabolic or endocrine disturbances</span><span class="headingEndMark"> — </span>Hypoglycemia, hypernatremia, hyponatremia, hypomagnesemia, and hypocalcemia have also been implicated in the development of acute or subacute chorea [<a href="#rid2">2,33</a>]. In addition, a few case reports have linked chorea to vitamin B12 deficiency [<a href="#rid64">64-66</a>]. Correction of the metabolic abnormality leads to resolution of abnormal movements.</p><p>Chorea is rarely associated with hyperthyroidism (less than 2 percent of patients) and is usually abolished after successful treatment of thyrotoxicosis [<a href="#rid67">67-69</a>]. Hypoparathyroidism often leads to hypocalcemia, which can produce generalized or focal chorea that is often paroxysmal and triggered by action (called paroxysmal kinesigenic dyskinesias) [<a href="#rid2">2,70-72</a>].</p><p>Chronic acquired hepatocerebral degeneration can occur in any form of acquired liver disease and may produce chorea, as well as other movement disorders such as tremor, parkinsonism, myoclonus, or dystonia [<a href="#rid73">73</a>]. MRI shows hyperintense T1 signal in basal ganglia, thought to result from deposition of manganese [<a href="#rid73">73</a>].</p><p>Patients with renal failure rarely present with chorea that is reversible with dialysis [<a href="#rid74">74</a>].</p><p>Celiac disease has been described to present with rapidly progressive generalized chorea, which resolved after gluten-free dietary treatment [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H29672796"><span class="h2">Infectious diseases</span><span class="headingEndMark"> — </span>Many infectious diseases of the central nervous system may produce acute or insidious chorea  (<a class="graphic graphic_table graphicRef95650" href="/d/graphic/95650.html" rel="external">table 2</a>). Human immunodeficiency virus (HIV) infection has been reported as the most frequent cause of infectious chorea [<a href="#rid33">33</a>]. Fifty percent of patients with acquired immune deficiency syndrome (AIDS) develop movement disorders, with hemiballism-hemichorea and tremor being the most common, although it is rarely clinically disabling (3 percent) [<a href="#rid76">76</a>]. Abnormal movements can result either from direct action of the virus in the setting of HIV encephalitis, opportunistic infections (toxoplasmosis, syphilis, tuberculosis, etc), or drugs [<a href="#rid33">33,76,77</a>].</p><p>Acute bacterial meningitis, aseptic meningitis, tuberculous meningitis, encephalitis, Lyme disease, parasitic or fungal infections, as well as prion diseases have all been reported to cause chorea in some patients. Chorea has rarely been reported with viral encephalitis, including in cases of coronavirus disease 2019 (COVID-19) and herpes simplex virus infection [<a href="#rid78">78,79</a>].</p><p class="headingAnchor" id="H29672823"><span class="h2">Toxin exposure</span><span class="headingEndMark"> — </span>Although uncommon, exposure or intoxication with carbon monoxide, manganese, thallium, toluene, methanol, cyanide, or mercury can result in transient or permanent movement disorders, including chorea [<a href="#rid80">80</a>]. Recreative use of alcohol, amphetamines, cocaine, or heroin as well as glue-sniffing can also produce chorea.</p><p class="headingAnchor" id="H29672831"><span class="h2">Drug-induced chorea</span><span class="headingEndMark"> — </span>Many different drugs have been reported to cause chorea  (<a class="graphic graphic_table graphicRef95651" href="/d/graphic/95651.html" rel="external">table 3</a>), either as an acute phenomenon or as the consequence of long-term therapy. Certain drugs (eg, oral contraceptives and levodopa) seem to require preexisting basal ganglia dysfunction, such as a remote history of SC or Parkinson disease, in order to cause chorea; others seem to be more universally choreogenic [<a href="#rid1">1</a>]. Withdrawal of the offending agent is the treatment of choice but does not always lead to remission of abnormal movements.</p><p>Chronic exposure to a dopamine antagonist (eg, antipsychotics and antiemetics such as <a class="drug drug_general" data-topicid="9642" href="/d/drug information/9642.html" rel="external">metoclopramide</a> and <a class="drug drug_general" data-topicid="9816" href="/d/drug information/9816.html" rel="external">prochlorperazine</a>) that crosses the blood-brain barrier can lead to abnormal movements of the oro-bucco-lingual region called tardive dyskinesia; <a class="drug drug_general" data-topicid="8777" href="/d/drug information/8777.html" rel="external">domperidone</a> does not result in tardive dyskinesia because it does not cross the blood-brain barrier. Although tardive dyskinesia has been referred to as "chorea," the term "stereotypies" appears to be more appropriate to describe the stereotyped oro-bucco-lingual movements, as opposed to typical random and flowy choreiform movements [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/4909.html" rel="external">"Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"</a>.)</p><p>Tardive dyskinesia is rare in children. Chorea related to dopamine receptor blocker use in children tends to occur with rapid discontinuation of the drug (rather than chronic use) and is called withdrawal emergent syndrome. In this setting, chorea is not restricted to the orofacial muscles and is often associated with other types of abnormal movements. (See  <a class="medical medical_review" href="/d/html/4909.html" rel="external">"Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis", section on 'Children'</a>.)</p><p>Once the offending medication has been withdrawn, the resolution of tardive movements can be a slow process (months to years) and is not assured. The prevention and management of tardive dyskinesia are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4908.html" rel="external">"Tardive dyskinesia: Prevention, treatment, and prognosis"</a>.)</p><p>Levodopa-induced motor fluctuations and dyskinesia eventually develop in more than 50 percent of patients with Parkinson disease depending on current age, age at disease onset, and duration of levodopa treatment. Levodopa-induced dyskinesias consist of abnormal involuntary movements that are usually choreic or dystonic but may be ballistic or myoclonic when more severe. (See  <a class="medical medical_review" href="/d/html/4893.html" rel="external">"Medical management of motor fluctuations and dyskinesia in Parkinson disease"</a>.)</p><p>Oral contraceptive use can result in unilateral or generalized insidious chorea, especially in individuals with previous SC, chorea gravidarum, SLE, or antiphospholipid syndrome [<a href="#rid81">81</a>]. Time between initiation of treatment and appearance of abnormal movements can vary from days to years [<a href="#rid81">81</a>]. Hormone replacement therapy inducing chorea in postmenopausal women has also been described [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H29672839"><span class="h2">Structural lesion in basal ganglia</span><span class="headingEndMark"> — </span>Any appropriately placed deep brain lesion (space occupying lesion, vascular lesion, infection, trauma, etc) can cause typical distal chorea or more proximal ballistic movements.</p><p class="headingAnchor" id="H29672854"><span class="h2">Senile chorea</span><span class="headingEndMark"> — </span>Senile chorea is a controversial entity previously referring to development of chorea in old age. However, investigation of these patients often reveals alternative diagnoses, the most common being Huntington disease (HD) [<a href="#rid33">33,82,83</a>].</p><p class="headingAnchor" id="H414422080"><span class="h2">Edentulous dyskinesia</span><span class="headingEndMark"> — </span>Older adult patients can exhibit choreic-like movements of the lips, tongue, and jaw associated with ill-fitting dentures or lack of dentures, referred to as "edentulous dyskinesia" [<a href="#rid84">84,85</a>]. This condition has been reported in up to 16 percent of edentulous patients [<a href="#rid85">85</a>]. It is thought that malocclusion or lack of sensory contact may play a role in the production of such orodyskinesia [<a href="#rid85">85</a>]. Insertion of well-fitting dentures can abate abnormal movements [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H29672862"><span class="h1">EVALUATION FOR THE CAUSE OF CHOREA</span><span class="headingEndMark"> — </span>To identify the cause of chorea in a particular patient, a careful history should include age of onset, time course (acute or insidious), past medical history, history of recent infection with group A beta-hemolytic streptococcus (GABHS), family history, and drug exposure  (<a class="graphic graphic_table graphicRef95651" href="/d/graphic/95651.html" rel="external">table 3</a>). Chronic and progressive chorea is typical of neurodegenerative diseases, whereas static chorea can be seen in structural or toxic injuries to basal ganglia or in benign hereditary chorea. Subacute or acute chorea can occur with autoimmune, metabolic, vascular, infectious, or toxic causes. Neurologic examination is also crucial and must include distribution of chorea and associated features.</p><p class="bulletIndent1"><span class="glyph">●</span>Hemichorea can occur due to a structural lesion. However, unilateral or asymmetric symptoms may also occur with autoimmune and metabolic choreas as well as chorea gravidarum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chorea associated with ataxia raises the suspicion for spinocerebellar ataxia (SCA) types 1, 2, 3, 8, or 17, dentatorubral pallidoluysian atrophy (DRPLA), ataxia-telangiectasia, ataxia with oculomotor apraxia types 1 (AOA1) or 2 (AOA2), and even rarely Friedreich ataxia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chorea associated with dementia suggests Huntington disease (HD), <em>C9ORF72</em> gene mutations, Huntington disease-like (HDL) syndromes, SCA17, DRPLA, or chorea-acanthocytosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chorea associated with signs of peripheral neuropathy can occur in chorea-acanthocytosis, McLeod syndrome, SCA, ataxia-telangiectasia, or AOA1 or AOA2.</p><p></p><p>To rule out a secondary cause, a basic workup includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Serum glucose and electrolytes</p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium, magnesium, vitamin B12, and parathyroid levels</p><p class="bulletIndent1"><span class="glyph">●</span>Renal, liver, and thyroid function tests</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test</p><p></p><p>Blood smear may reveal the presence of acanthocytes in chorea-acanthocytosis, McLeod syndrome, HDL2, and pantothenate kinase-associated neurodegeneration (PKAN). In suspected Sydenham chorea (SC), other major or minor symptoms and signs of rheumatic fever should be sought, including evaluation for carditis; antideoxyribonuclease B and antistreptolysin O titers can be helpful. Screening for possible autoimmune chorea includes antinuclear antibodies and antiphospholipid antibodies, while a paraneoplastic evaluation would add anti-CRMP5/CV2, anti-Hu, anti-Yo, anti-Ri, anti-NMDA, anti-LGI1, and anti-Caspr2 antibodies.</p><p>Screening for Wilson disease with serum ceruloplasmin and 24-hour urine copper is recommended in any case of movement disorder under the age of 40 years, especially if there is a positive family history of neuropsychiatric disorders or a history of liver disease. Workup for infectious causes of chorea should be directed by the clinical setting and degree of suspicion for particular infections. Specific considerations in appropriate settings include HIV testing, lumbar puncture for cerebrospinal fluid (CSF) examination (including Venereal Disease Research Laboratory [VDRL]), Lyme serologies, and toxoplasmosis titers (in immunosuppressed patients).</p><p>Neuroimaging with brain MRI (preferred) or CT will help to rule out a structural lesion in patients with focal or unilateral choreas, but may also reveal evidence of hereditary, immunologic, or metabolic choreas, such as caudate and frontal atrophy in HD, cerebellar atrophy in SCA, or basal ganglia anomalies in neuroferritinopathy, chorea-acanthocytosis, Wilson disease, PKAN, liver dysfunction, or hyperglycemia.</p><p>Genetic testing is available for many hereditary choreas, which allows confirmation of the diagnosis and genetic counseling to family members.</p><p class="headingAnchor" id="H29672870"><span class="h1">MANAGEMENT OF CHOREA</span><span class="headingEndMark"> — </span>Secondary chorea often improves or resolves with appropriate treatment of the underlying cause or withdrawal of the offending agent. Unfortunately, no agent has been proven to slow or halt progression of hereditary choreas, with the exception of copper-reducing therapies in Wilson disease. Clinical trials are underway to reduce expression of mutated huntingtin in HD, hoping to slow progression or delay onset of disease.</p><p>The mainstay of management in genetic choreas includes careful genetic counseling of affected patients and their relatives and symptomatic treatment of chorea and other symptoms if they cause functional disability or social embarrassment. The same agents used to reduce choreic movements in primary chorea can also be used for secondary chorea, although treatment is often unnecessary because many patients are unaware of or untroubled by the movements.</p><p>The management of specific causes of chorea is reviewed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Huntington disease (HD) (see  <a class="medical medical_review" href="/d/html/4902.html" rel="external">"Huntington disease: Management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Levodopa-induced dyskinesia in Parkinson disease (see  <a class="medical medical_review" href="/d/html/4893.html" rel="external">"Medical management of motor fluctuations and dyskinesia in Parkinson disease"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sydenham chorea (SC) (see  <a class="medical medical_review" href="/d/html/6228.html" rel="external">"Sydenham chorea", section on 'Treatment'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wilson disease (see  <a class="medical medical_review" href="/d/html/3591.html" rel="external">"Wilson disease: Management"</a>)</p><p></p><p>Symptomatically, dopamine receptor blockers have been generally considered the most effective agents to reduce the severity of choreic movements, regardless of the cause. First-generation antipsychotic agents (typical neuroleptics) have a long history of use to reduce chorea, although there is little evidence to support their efficacy, and they are increasingly avoided due to higher risk of side effects.</p><p>Second-generation antipsychotic drugs (atypical neuroleptics) including <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, and <a class="drug drug_general" data-topicid="8786" href="/d/drug information/8786.html" rel="external">aripiprazole</a> can help reduce chorea and may have a better side effect profile. Common side effects and risks of second-generation agents, including weight gain and related metabolic effects, should be reviewed with the patient when considering long-term therapy. In the authors' experience, <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> is not helpful for control of chorea, except in very high doses (eg, 300 mg daily). (See  <a class="medical medical_review" href="/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'</a>.)</p><p>Dopamine depleting agents also have the potential to treat chorea. In particular, inhibitors of presynaptic vesicular monoamine transporter type 2 (VMAT2) such as <a class="drug drug_general" data-topicid="9476" href="/d/drug information/9476.html" rel="external">tetrabenazine</a>, <a class="drug drug_general" data-topicid="112668" href="/d/drug information/112668.html" rel="external">valbenazine</a>, and <a class="drug drug_general" data-topicid="112590" href="/d/drug information/112590.html" rel="external">deutetrabenazine</a> are now a first-line option for chorea associated with HD and are also becoming a treatment of choice for chorea of any cause [<a href="#rid86">86-88</a>]. Clinicians should be aware of the risk of depression with VMAT inhibitors as well as the potential for a variety of important drug interactions. (See  <a class="medical medical_review" href="/d/html/4902.html" rel="external">"Huntington disease: Management", section on 'Management of chorea'</a>.)</p><p>Although evidence is limited, <a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">valproic acid</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>, <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, <a class="drug drug_general" data-topicid="9904" href="/d/drug information/9904.html" rel="external">levetiracetam</a>, <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, and levodopa may be useful to suppress chorea in some patients [<a href="#rid89">89-104</a>].</p><p>Autoimmune choreas including autoimmune or paraneoplastic encephalitis, systemic lupus erythematosus (SLE), and antiphospholipid antibody syndrome may be responsive to treatment with glucocorticoids, plasma exchange, or intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>) [<a href="#rid102">102,105-109</a>].</p><p>Clinical experience suggests that benzodiazepines have a mild antichorea effect, but the use of such agents is poorly documented [<a href="#rid110">110</a>].</p><p>Although surgical therapy (eg, pallidotomy, thalamotomy, deep brain stimulation) has been reported to reduce chorea in case reports and small series, it is not generally recommended in HD, vascular chorea, cerebral palsy, senile chorea, or dentatorubral pallidoluysian atrophy (DRPLA) due to lack of proven efficacy and risk of side effects [<a href="#rid111">111-115</a>]. If used, surgical therapies should be considered carefully and only in patients with no cognitive abnormalities.</p><p class="headingAnchor" id="H29672514"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Chorea is a hyperkinetic movement disorder characterized by rapid and unpredictable contractions affecting mostly distal limbs, but also the face and trunk. The movements are involuntary and nonpatterned, with variable speed, timing, and direction. (See <a class="local">'Definitions'</a> above.)</p><p></p><p class="bulletIndent1">The continuous flow of choreiform movements may appear semipurposeful and difficult to distinguish from restless or fidgety behavior. Chorea disappears in sleep. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localization</strong> – The structures involved in the production of chorea are the caudate nucleus, putamen, subthalamic nucleus, thalamus, and their interconnecting pathways. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Chorea is usually classified as being primary (idiopathic, hereditary) or secondary (acquired). Hereditary choreas tend to develop insidiously and are generally symmetrical, whereas acquired choreas are more likely to be acute or subacute and can be asymmetrical or unilateral. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hereditary causes</strong> – There are many different causes of hereditary chorea  (<a class="graphic graphic_table graphicRef95649" href="/d/graphic/95649.html" rel="external">table 1</a>). Patterns of inheritance include autosomal dominant, autosomal recessive, and X-linked.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autosomal dominant</strong> – Important autosomal-dominant causes include Huntington disease (HD), <em>C9ORF72</em> repeat expansions, Huntington disease-like (HDL) syndromes, benign hereditary chorea, dentatorubral pallidoluysian atrophy (DRPLA), several types of spinocerebellar ataxia (SCA), and neuroferritinopathy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autosomal recessive </strong>–<strong> </strong>Important autosomal-recessive causes of hereditary chorea include chorea-acanthocytosis, Wilson disease, pantothenate kinase-associated neurodegeneration (PKAN), ataxia-telangiectasia, and ataxia with oculomotor apraxia (AOA).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>X-linked</strong> –<strong> </strong>The main X-linked causes of chorea include McLeod syndrome and Lesch-Nyhan syndrome. (See <a class="local">'Hereditary causes of chorea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acquired causes</strong> – A variety of acquired conditions can cause chorea  (<a class="graphic graphic_table graphicRef95650" href="/d/graphic/95650.html" rel="external">table 2</a>). These include central nervous system vascular lesions; autoimmune/inflammatory disorders, particularly Sydenham chorea; metabolic and endocrine disorders; infectious diseases; toxins; drugs  (<a class="graphic graphic_table graphicRef95651" href="/d/graphic/95651.html" rel="external">table 3</a>); structural lesions of the basal ganglia; and so-called senile chorea. (See <a class="local">'Acquired causes of chorea'</a> above.)</p><p></p><p class="bulletIndent1">In children, most cases of chorea are acquired and develop acutely or subacutely, the most common etiology being Sydenham chorea. (See <a class="local">'Sydenham chorea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – A careful history should include age of onset, time course (acute or insidious), past medical history, history of recent infection with group A beta-hemolytic streptococcus (GABHS), family history, and drug exposure  (<a class="graphic graphic_table graphicRef95651" href="/d/graphic/95651.html" rel="external">table 3</a>). Neuroimaging should be performed for new-onset cases, especially when asymmetric. A variety of laboratory tests may be useful depending on the clinical context. (See <a class="local">'Evaluation for the cause of chorea'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment of chorea is symptomatic. Secondary chorea often improves or resolves with appropriate treatment of the underlying cause or withdrawal of the offending agent. Dopamine receptor blockers can reduce the severity of choreic movements, regardless of the cause. (See <a class="local">'Management of chorea'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cardoso F, Seppi K, Mair KJ, et al. Seminar on choreas. Lancet Neurol 2006; 5:589.</a></li><li><a class="nounderline abstract_t">Bhidayasiri R, Truong DD. Chorea and related disorders. Postgrad Med J 2004; 80:527.</a></li><li><a class="nounderline abstract_t">Suchowersky O, Muthipeedika J. A case of late-onset chorea. Nat Clin Pract Neurol 2005; 1:113.</a></li><li><a class="nounderline abstract_t">Termsarasab P. Chorea. Continuum (Minneap Minn) 2019; 25:1001.</a></li><li><a class="nounderline abstract_t">Shannon KM. Treatment of chorea. Continuum 2007; 13:72.</a></li><li><a class="nounderline abstract_t">Lee MS, Marsden CD. Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord 1994; 9:493.</a></li><li><a class="nounderline abstract_t">Piccolo I, Defanti CA, Soliveri P, et al. Cause and course in a series of patients with sporadic chorea. J Neurol 2003; 250:429.</a></li><li><a class="nounderline abstract_t">Zomorrodi A, Wald ER. Sydenham's chorea in western Pennsylvania. Pediatrics 2006; 117:e675.</a></li><li><a class="nounderline abstract_t">Hensman Moss DJ, Poulter M, Beck J, et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 2014; 82:292.</a></li><li><a class="nounderline abstract_t">Schneider SA, Walker RH, Bhatia KP. The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test. Nat Clin Pract Neurol 2007; 3:517.</a></li><li><a class="nounderline abstract_t">Gövert F, Schneider SA. Huntington's disease and Huntington's disease-like syndromes: an overview. Curr Opin Neurol 2013; 26:420.</a></li><li><a class="nounderline abstract_t">Xiang F, Almqvist EW, Huq M, et al. A Huntington disease-like neurodegenerative disorder maps to chromosome 20p. Am J Hum Genet 1998; 63:1431.</a></li><li><a class="nounderline abstract_t">Margolis RL, Holmes SE, Rosenblatt A, et al. Huntington's Disease-like 2 (HDL2) in North America and Japan. Ann Neurol 2004; 56:670.</a></li><li><a class="nounderline abstract_t">Wild EJ, Mudanohwo EE, Sweeney MG, et al. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008; 23:716.</a></li><li><a class="nounderline abstract_t">Santos C, Wanderley H, Vedolin L, et al. Huntington disease-like 2: the first patient with apparent European ancestry. Clin Genet 2008; 73:480.</a></li><li><a class="nounderline abstract_t">Walker RH, Jung HH, Dobson-Stone C, et al. Neurologic phenotypes associated with acanthocytosis. Neurology 2007; 68:92.</a></li><li><a class="nounderline abstract_t">Walker RH, Rasmussen A, Rudnicki D, et al. Huntington's disease--like 2 can present as chorea-acanthocytosis. Neurology 2003; 61:1002.</a></li><li><a class="nounderline abstract_t">Kambouris M, Bohlega S, Al-Tahan A, Meyer BF. Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am J Hum Genet 2000; 66:445.</a></li><li><a class="nounderline abstract_t">Wild EJ, Tabrizi SJ. Huntington's disease phenocopy syndromes. Curr Opin Neurol 2007; 20:681.</a></li><li><a class="nounderline abstract_t">Stevanin G, Brice A. Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum 2008; 7:170.</a></li><li><a class="nounderline abstract_t">Schneider SA, Bird T. Huntington's Disease, Huntington's Disease Look-Alikes‎, and Benign Hereditary Chorea: What's New? Mov Disord Clin Pract 2016; 3:342.</a></li><li><a class="nounderline abstract_t">Invernizzi F, Zorzi G, Legati A, et al. Benign hereditary chorea and deletions outside NKX2-1: What's the role of MBIP? Eur J Med Genet 2018; 61:581.</a></li><li><a class="nounderline abstract_t">Millichap JG. ADCY5 Mutations and Benign Hereditary Chorea. Pediatr Neurol Briefs 2015; 29:70.</a></li><li><a class="nounderline abstract_t">Devos D, Tchofo PJ, Vuillaume I, et al. Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain 2009; 132:e109.</a></li><li><a class="nounderline abstract_t">Breedveld GJ, van Dongen JW, Danesino C, et al. Mutations in TITF-1 are associated with benign hereditary chorea. Hum Mol Genet 2002; 11:971.</a></li><li><a class="nounderline abstract_t">Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001; 28:350.</a></li><li><a class="nounderline abstract_t">Chinnery PF, Curtis AR, Fey C, et al. Neuroferritinopathy in a French family with late onset dominant dystonia. J Med Genet 2003; 40:e69.</a></li><li><a class="nounderline abstract_t">Maciel P, Cruz VT, Constante M, et al. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology 2005; 65:603.</a></li><li><a class="nounderline abstract_t">Batla A, Adams ME, Erro R, et al. Cortical pencil lining in neuroferritinopathy: a diagnostic clue. Neurology 2015; 84:1816.</a></li><li><a class="nounderline abstract_t">Mencacci NE, Carecchio M. Recent advances in genetics of chorea. Curr Opin Neurol 2016; 29:486.</a></li><li><a class="nounderline abstract_t">Carecchio M, Mencacci NE, Iodice A, et al. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord 2017; 41:37.</a></li><li><a class="nounderline abstract_t">Narayanan DL, Deshpande D, Das Bhowmik A, et al. Familial choreoathetosis due to novel heterozygous mutation in PDE10A. Am J Med Genet A 2018; 176:146.</a></li><li><a class="nounderline abstract_t">Harper PS. The epidemiology of Huntington's disease. Hum Genet 1992; 89:365.</a></li><li><a class="nounderline abstract_t">Ghika-Schmid F, Ghika J, Regli F, Bogousslavsky J. Hyperkinetic movement disorders during and after acute stroke: the Lausanne Stroke Registry. J Neurol Sci 1997; 146:109.</a></li><li><a class="nounderline abstract_t">Chung SJ, Im JH, Lee MC, Kim JS. Hemichorea after stroke: clinical-radiological correlation. J Neurol 2004; 251:725.</a></li><li><a class="nounderline abstract_t">Postuma RB, Lang AE. Hemiballism: revisiting a classic disorder. Lancet Neurol 2003; 2:661.</a></li><li><a class="nounderline abstract_t">Alarcón F, Zijlmans JC, Dueñas G, Cevallos N. Post-stroke movement disorders: report of 56 patients. J Neurol Neurosurg Psychiatry 2004; 75:1568.</a></li><li><a class="nounderline abstract_t">Laganiere S, Boes AD, Fox MD. Network localization of hemichorea-hemiballismus. Neurology 2016; 86:2187.</a></li><li><a class="nounderline abstract_t">Ahn JH, Song J, Choi I, et al. Risk factors and prognosis of adult-onset post-pump chorea. J Neurol Sci 2021; 422:117328.</a></li><li><a class="nounderline abstract_t">Nazabal ER, Lopez JM, Perez PA, Del Corral PR. Chorea disclosing deterioration of polycythaemia vera. Postgrad Med J 2000; 76:658.</a></li><li><a class="nounderline abstract_t">O'Toole O, Lennon VA, Ahlskog JE, et al. Autoimmune chorea in adults. Neurology 2013; 80:1133.</a></li><li><a class="nounderline abstract_t">Mehta SH, Morgan JC, Sethi KD. Paraneoplastic movement disorders. Curr Neurol Neurosci Rep 2009; 9:285.</a></li><li><a class="nounderline abstract_t">Vigliani MC, Honnorat J, Antoine JC, et al. Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. J Neurol 2011; 258:2058.</a></li><li><a class="nounderline abstract_t">Barton B, Zauber SE, Goetz CG. Movement disorders caused by medical disease. Semin Neurol 2009; 29:97.</a></li><li><a class="nounderline abstract_t">Martinková J, Valkovic P, Benetin J. Paraneoplastic chorea associated with breast cancer. Mov Disord 2009; 24:2296.</a></li><li><a class="nounderline abstract_t">Kellinghaus C, Kraus J, Blaes F, et al. CRMP-5-autoantibodies in testicular cancer associated with limbic encephalitis and choreiform dyskinesias. Eur Neurol 2007; 57:241.</a></li><li><a class="nounderline abstract_t">Lee EK, Maselli RA, Ellis WG, Agius MA. Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry 1998; 65:857.</a></li><li><a class="nounderline abstract_t">Balint B, Vincent A, Meinck HM, et al. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain 2018; 141:13.</a></li><li><a class="nounderline abstract_t">Sturchio A, Dwivedi AK, Gastaldi M, et al. Movement disorders associated with neuronal antibodies: a data-driven approach. J Neurol 2022; 269:3511.</a></li><li><a class="nounderline abstract_t">Kruer MC, Hoeftberger R, Lim KY, et al. Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case of γ-aminobutyric acid type B receptor autoimmunity. JAMA Neurol 2014; 71:620.</a></li><li><a class="nounderline abstract_t">Arnson Y, Shoenfeld Y, Alon E, Amital H. The antiphospholipid syndrome as a neurological disease. Semin Arthritis Rheum 2010; 40:97.</a></li><li><a class="nounderline abstract_t">Benamour S, Naji T, Alaoui FZ, et al. [Neurological involvement in Behçet's disease. 154 cases from a cohort of 925 patients and review of the literature]. Rev Neurol (Paris) 2006; 162:1084.</a></li><li><a class="nounderline abstract_t">Venegas Fanchke P, Sinning M, Miranda M. Primary Sjogren's syndrome presenting as a generalized chorea. Parkinsonism Relat Disord 2005; 11:193.</a></li><li><a class="nounderline abstract_t">Duzova A, Bakkaloglu A. Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment. Curr Pharm Des 2008; 14:1295.</a></li><li><a class="nounderline abstract_t">Bushara KO. Neurologic presentation of celiac disease. Gastroenterology 2005; 128:S92.</a></li><li><a class="nounderline abstract_t">Sigal LH. The neurologic presentation of vasculitic and rheumatologic syndromes. A review. Medicine (Baltimore) 1987; 66:157.</a></li><li><a class="nounderline abstract_t">Nissen MS, Blaabjerg M. Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature. Front Neurol 2019; 10:1056.</a></li><li><a class="nounderline abstract_t">Bordelon YM, Smith M. Movement disorders in pregnancy. Semin Neurol 2007; 27:467.</a></li><li><a class="nounderline abstract_t">Gómez-Ochoa SA, Espín-Chico BB, Pinilla-Monsalve GD, et al. Clinical and neuroimaging spectrum of hyperglycemia-associated chorea-ballism: systematic review and exploratory analysis of case reports. Funct Neurol 2018; 33:175.</a></li><li><a class="nounderline abstract_t">Chang CV, Felicio AC, Godeiro Cde O Jr, et al. Chorea-ballism as a manifestation of decompensated type 2 diabetes mellitus. Am J Med Sci 2007; 333:175.</a></li><li><a class="nounderline abstract_t">Chua CB, Sun CK, Hsu CW, et al. "Diabetic striatopathy": clinical presentations, controversy, pathogenesis, treatments, and outcomes. Sci Rep 2020; 10:1594.</a></li><li><a class="nounderline abstract_t">Lee BC, Hwang SH, Chang GY. Hemiballismus-hemichorea in older diabetic women: a clinical syndrome with MRI correlation. Neurology 1999; 52:646.</a></li><li><a class="nounderline abstract_t">Cai L, Tan XZ. Hemichorea in a woman with diabetes mellitus. CMAJ 2022; 194:E812.</a></li><li><a class="nounderline abstract_t">Pacchetti C, Cristina S, Nappi G. Reversible chorea and focal dystonia in vitamin B12 deficiency. N Engl J Med 2002; 347:295.</a></li><li><a class="nounderline abstract_t">Shyambabu C, Sinha S, Taly AB, et al. Serum vitamin B12 deficiency and hyperhomocystinemia: a reversible cause of acute chorea, cerebellar ataxia in an adult with cerebral ischemia. J Neurol Sci 2008; 273:152.</a></li><li><a class="nounderline abstract_t">Edvardsson B, Persson S. Chorea associated with vitamin B12 deficiency. Eur J Neurol 2011; 18:e138.</a></li><li><a class="nounderline abstract_t">Ristić AJ, Svetel M, Dragasević N, et al. Bilateral chorea-ballism associated with hyperthyroidism. Mov Disord 2004; 19:982.</a></li><li><a class="nounderline abstract_t">Yu JH, Weng YM. Acute chorea as a presentation of Graves disease: case report and review. Am J Emerg Med 2009; 27:369.e1.</a></li><li><a class="nounderline abstract_t">Docherty MJ, Burn DJ. Hyperthyroid chorea. Handb Clin Neurol 2011; 100:279.</a></li><li><a class="nounderline abstract_t">Topakian R, Stieglbauer K, Rotaru J, et al. Hypocalcemic choreoathetosis and tetany after bisphosphonate treatment. Mov Disord 2006; 21:2026.</a></li><li><a class="nounderline abstract_t">Thomas R, Behari M, Gaikwad SB, Prasad K. An unusual case of paroxysmal kinesigenic dyskinesia. J Clin Neurosci 2002; 9:94.</a></li><li><a class="nounderline abstract_t">Rao YP, Naidu KS, Murthy JM. Idiopathic hypoparathyroidism with extensive intracranial calcification associated with kinesigenic choreoathetosis. J Assoc Physicians India 1999; 47:928.</a></li><li><a class="nounderline abstract_t">Jog MS, Lang AE. Chronic acquired hepatocerebral degeneration: case reports and new insights. Mov Disord 1995; 10:714.</a></li><li><a class="nounderline abstract_t">Lee EJ, Park JH, Ihn Yk, et al. Acute bilateral basal ganglia lesions in diabetic uraemia: diffusion-weighted MRI. Neuroradiology 2007; 49:1009.</a></li><li><a class="nounderline abstract_t">Lefter S, Corcoran L, McAuliffe E, et al. Coeliac disease presenting with chorea. Pract Neurol 2020; 20:144.</a></li><li><a class="nounderline abstract_t">Cardoso F. HIV-related movement disorders: epidemiology, pathogenesis and management. CNS Drugs 2002; 16:663.</a></li><li><a class="nounderline abstract_t">Gallo BV, Shulman LM, Weiner WJ, et al. HIV encephalitis presenting with severe generalized chorea. Neurology 1996; 46:1163.</a></li><li><a class="nounderline abstract_t">Sawczyńska K, Wężyk K, Bosak M, et al. Acute-onset chorea and confusional state in 77-year-old COVID-19 patient: a case report. Neurol Neurochir Pol 2022; 56:106.</a></li><li><a class="nounderline abstract_t">Kolesnik M, Ballout AA, Hameed N, Najjar S. Case Report: HSV-2 Encephalitis Presenting With Chorea; Effects of Infection Alone or Combination of Infection and Autoimmunity? Front Neurol 2021; 12:790514.</a></li><li><a class="nounderline abstract_t">Miyasaki JM. Chorea caused by toxins. Handb Clin Neurol 2011; 100:335.</a></li><li><a class="nounderline abstract_t">Miranda M, Cardoso F, Giovannoni G, Church A. Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry 2004; 75:327.</a></li><li><a class="nounderline abstract_t">Warren JD, Firgaira F, Thompson EM, et al. The causes of sporadic and 'senile' chorea. Aust N Z J Med 1998; 28:429.</a></li><li><a class="nounderline abstract_t">Kimber TE, Thompson PD. Senile chorea. Handb Clin Neurol 2011; 100:213.</a></li><li><a class="nounderline abstract_t">Blanchet PJ, Rompré PH, Lavigne GJ, Lamarche C. Oral dyskinesia: a clinical overview. Int J Prosthodont 2005; 18:10.</a></li><li><a class="nounderline abstract_t">Blanchet PJ, Popovici R, Guitard F, et al. Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects. Mov Disord 2008; 23:1837.</a></li><li><a class="nounderline abstract_t">Bashir H, Jankovic J. Treatment options for chorea. Expert Rev Neurother 2018; 18:51.</a></li><li><a class="nounderline abstract_t">Heo YA, Scott LJ. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease. Drugs 2017; 77:1857.</a></li><li><a class="nounderline abstract_t">Dean M, Sung VW. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Drug Des Devel Ther 2018; 12:313.</a></li><li><a class="nounderline abstract_t">Harel L, Zecharia A, Straussberg R, et al. Successful treatment of rheumatic chorea with carbamazepine. Pediatr Neurol 2000; 23:147.</a></li><li><a class="nounderline abstract_t">Chandra V, Spunt AL, Rusinowitz MS. Treatment of post-traumatic choreo-athetosis with sodium valproate. J Neurol Neurosurg Psychiatry 1983; 46:963.</a></li><li><a class="nounderline abstract_t">Giroud M, Dumas R. Valproate sodium in postanoxic choreoathetosis. J Child Neurol 1986; 1:80.</a></li><li><a class="nounderline abstract_t">Kulkarni ML. Sodium valproate controls choreoathetoid movements of kernicterus. Indian Pediatr 1992; 29:1029.</a></li><li><a class="nounderline abstract_t">Lenton RJ, Copti M, Smith RG. Hemiballismus treated with sodium valproate. Br Med J (Clin Res Ed) 1981; 283:17.</a></li><li><a class="nounderline abstract_t">Siniscalchi A, Gallelli L, Davoli A, De Sarro G. Efficacy and tolerability of topiramate in vascular generalized chorea. Ann Pharmacother 2007; 41:1915.</a></li><li><a class="nounderline abstract_t">Driver-Dunckley E, Evidente VG. Hemichorea-hemiballismus may respond to topiramate. Clin Neuropharmacol 2005; 28:142.</a></li><li><a class="nounderline abstract_t">Gatto EM, Uribe Roca C, Raina G, et al. Vascular hemichorea/hemiballism and topiramate. Mov Disord 2004; 19:836.</a></li><li><a class="nounderline abstract_t">Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Mov Disord 2006; 21:1998.</a></li><li><a class="nounderline abstract_t">Zesiewicz TA, Pathak A, Sullivan KL, et al. Treatment of chorea with levetiracetam. Eur J Clin Pharmacol 2006; 62:87.</a></li><li><a class="nounderline abstract_t">Tsao CY. Effective treatment with oxcarbazepine in paroxysmal kinesigenic choreoathetosis. J Child Neurol 2004; 19:300.</a></li><li><a class="nounderline abstract_t">Kothare SV, Pollack P, Kulberg AG, Ravin PD. Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus. Pediatr Neurol 2000; 22:68.</a></li><li><a class="nounderline abstract_t">Chudnow RS, Mimbela RA, Owen DB, Roach ES. Gabapentin for familial paroxysmal dystonic choreoathetosis. Neurology 1997; 49:1441.</a></li><li><a class="nounderline abstract_t">Cardoso F, Maia D, Cunningham MC, Valença G. Treatment of Sydenham chorea with corticosteroids. Mov Disord 2003; 18:1374.</a></li><li><a class="nounderline abstract_t">Bouchal S, Ouali O, Belahsen MF. [Exceptionally good response to sodium valproate in patients with recurrent Sydenham's chorea]. Pan Afr Med J 2017; 27:212.</a></li><li><a class="nounderline abstract_t">Farrenburg M, Gupta HV. Levodopa-Responsive Chorea: A Review. Ann Indian Acad Neurol 2020; 23:211.</a></li><li><a class="nounderline abstract_t">Paz JA, Silva CA, Marques-Dias MJ. Randomized double-blind study with prednisone in Sydenham's chorea. Pediatr Neurol 2006; 34:264.</a></li><li><a class="nounderline abstract_t">Sanna G, Bertolaccini ML, Khamashta MA. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 2008; 14:1261.</a></li><li><a class="nounderline abstract_t">Cervera R, Bucciarelli S, Plasín MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun 2009; 32:240.</a></li><li><a class="nounderline abstract_t">Weinstein R. Therapeutic apheresis in neurological disorders: a survey of the evidence in support of current category I and II indications for therapeutic plasma exchange. J Clin Apher 2008; 23:196.</a></li><li><a class="nounderline abstract_t">Fusco C, Spagnoli C. Corticosteroid treatment in Sydenham's chorea. Eur J Paediatr Neurol 2018; 22:327.</a></li><li><a class="nounderline abstract_t">Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976; 1:225.</a></li><li><a class="nounderline abstract_t">Goto S, Kunitoku N, Hamasaki T, et al. Abolition of postapoplectic hemichorea by Vo-complex thalamotomy: long-term follow-up study. Mov Disord 2001; 16:771.</a></li><li><a class="nounderline abstract_t">Choi SJ, Lee SW, Kim MC, et al. Posteroventral pallidotomy in medically intractable postapoplectic monochorea: case report. Surg Neurol 2003; 59:486.</a></li><li><a class="nounderline abstract_t">Yianni J, Nandi D, Bradley K, et al. Senile chorea treated by deep brain stimulation: a clinical, neurophysiological and functional imaging study. Mov Disord 2004; 19:597.</a></li><li><a class="nounderline abstract_t">Watarai M, Hashimoto T, Yamamoto K, et al. Pallidotomy for severe generalized chorea of juvenile-onset dentatorubral-pallidoluysian atrophy. Neurology 2003; 61:1452.</a></li><li><a class="nounderline abstract_t">Edwards TC, Zrinzo L, Limousin P, Foltynie T. Deep brain stimulation in the treatment of chorea. Mov Disord 2012; 27:357.</a></li></ol></div><div id="topicVersionRevision">Topic 14133 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16781989" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Seminar on choreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356354" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Chorea and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16932507" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A case of late-onset chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356291" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of chorea</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7990845" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Movement disorders following lesions of the thalamus or subthalamic region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700907" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cause and course in a series of patients with sporadic chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16533893" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sydenham's chorea in western Pennsylvania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24363131" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17805246" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812307" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Huntington's disease and Huntington's disease-like syndromes: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792871" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Huntington disease-like neurodegenerative disorder maps to chromosome 20p.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15468075" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Huntington's Disease-like 2 (HDL2) in North America and Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181206" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Huntington's disease phenocopies are clinically and genetically heterogeneous.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18341606" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Huntington disease-like 2: the first patient with apparent European ancestry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210889" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neurologic phenotypes associated with acanthocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557581" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Huntington's disease--like 2 can present as chorea-acanthocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10677304" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17992089" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Huntington's disease phenocopy syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18418687" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30713928" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Huntington's Disease, Huntington's Disease Look-Alikes‎, and Benign Hereditary Chorea: What's New?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29621620" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Benign hereditary chorea and deletions outside NKX2-1: What's the role of MBIP?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26933606" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ADCY5 Mutations and Benign Hereditary Chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18854324" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11971878" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutations in TITF-1 are associated with benign hereditary chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438811" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12746423" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neuroferritinopathy in a French family with late onset dominant dystonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116125" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25832658" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cortical pencil lining in neuroferritinopathy: a diagnostic clue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27257945" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Recent advances in genetics of chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28511835" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29130591" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Familial choreoathetosis due to novel heterozygous mutation in PDE10A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1535611" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The epidemiology of Huntington's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9077506" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hyperkinetic movement disorders during and after acute stroke: the Lausanne Stroke Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15311349" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hemichorea after stroke: clinical-radiological correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14572734" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hemiballism: revisiting a classic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15489389" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Post-stroke movement disorders: report of 56 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27170566" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Network localization of hemichorea-hemiballismus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33516056" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk factors and prognosis of adult-onset post-pump chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11009585" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chorea disclosing deterioration of polycythaemia vera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23427325" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Autoimmune chorea in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19515280" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Paraneoplastic movement disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21559939" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370491" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Movement disorders caused by medical disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845010" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Paraneoplastic chorea associated with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17389803" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : CRMP-5-autoantibodies in testicular cancer associated with limbic encephalitis and choreiform dyskinesias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854961" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053777" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35024921" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Movement disorders associated with neuronal antibodies: a data-driven approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590315" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case ofγ-aminobutyric acid type B receptor autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19596138" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The antiphospholipid syndrome as a neurological disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17086145" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : [Neurological involvement in Behçet's disease. 154 cases from a cohort of 925 patients and review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15823485" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Primary Sjogren's syndrome presenting as a generalized chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18537653" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825133" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neurologic presentation of celiac disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3553845" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The neurologic presentation of vasculitic and rheumatologic syndromes. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31632341" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940926" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Movement disorders in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30663963" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Clinical and neuroimaging spectrum of hyperglycemia-associated chorea-ballism: systematic review and exploratory analysis of case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17496737" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Chorea-ballism as a manifestation of decompensated type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32005905" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : "Diabetic striatopathy": clinical presentations, controversy, pathogenesis, treatments, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025807" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hemiballismus-hemichorea in older diabetic women: a clinical syndrome with MRI correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35697370" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hemichorea in a woman with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12140313" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Reversible chorea and focal dystonia in vitamin B12 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18678379" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Serum vitamin B12 deficiency and hyperhomocystinemia: a reversible cause of acute chorea, cerebellar ataxia in an adult with cerebral ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21914048" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Chorea associated with vitamin B12 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300671" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bilateral chorea-ballism associated with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19328390" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Acute chorea as a presentation of Graves disease: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496587" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hyperthyroid chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16972252" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hypocalcemic choreoathetosis and tetany after bisphosphonate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11749031" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : An unusual case of paroxysmal kinesigenic dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10778668" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Idiopathic hypoparathyroidism with extensive intracranial calcification associated with kinesigenic choreoathetosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749990" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Chronic acquired hepatocerebral degeneration: case reports and new insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17922120" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acute bilateral basal ganglia lesions in diabetic uraemia: diffusion-weighted MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31780451" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Coeliac disease presenting with chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12269860" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : HIV-related movement disorders: epidemiology, pathogenesis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8780114" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : HIV encephalitis presenting with severe generalized chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34985113" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acute-onset chorea and confusional state in 77-year-old COVID-19 patient: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34956068" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Case Report: HSV-2 Encephalitis Presenting With Chorea; Effects of Infection Alone or Combination of Infection and Autoimmunity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496593" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Chorea caused by toxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14742621" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9777108" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The causes of sporadic and 'senile' chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496580" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Senile chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15754887" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Oral dyskinesia: a clinical overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759358" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pain and denture condition in edentulous orodyskinesia: comparisons with tardive dyskinesia and control subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29120264" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Treatment options for chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29080203" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29497277" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11020640" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Successful treatment of rheumatic chorea with carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6417281" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Treatment of post-traumatic choreo-athetosis with sodium valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3110259" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Valproate sodium in postanoxic choreoathetosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1281140" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Sodium valproate controls choreoathetoid movements of kernicterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6788243" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hemiballismus treated with sodium valproate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17911204" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Efficacy and tolerability of topiramate in vascular generalized chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965315" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hemichorea-hemiballismus may respond to topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15254947" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Vascular hemichorea/hemiballism and topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941461" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16320048" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Treatment of chorea with levetiracetam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15163097" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Effective treatment with oxcarbazepine in paroxysmal kinesigenic choreoathetosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669210" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371936" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Gabapentin for familial paroxysmal dystonic choreoathetosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639684" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Treatment of Sydenham chorea with corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28979614" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : [Exceptionally good response to sodium valproate in patients with recurrent Sydenham's chorea].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32189864" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Levodopa-Responsive Chorea: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638499" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Randomized double-blind study with prednisone in Sydenham's chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18537650" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324520" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973115" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Therapeutic apheresis in neurological disorders: a survey of the evidence in support of current category I and II indications for therapeutic plasma exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29287833" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Corticosteroid treatment in Sydenham's chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/131236" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Clonazepam in the treatment of choreiform activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11481712" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Abolition of postapoplectic hemichorea by Vo-complex thalamotomy: long-term follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12826351" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Posteroventral pallidotomy in medically intractable postapoplectic monochorea: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15133831" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Senile chorea treated by deep brain stimulation: a clinical, neurophysiological and functional imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14638982" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Pallidotomy for severe generalized chorea of juvenile-onset dentatorubral-pallidoluysian atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21997283" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Deep brain stimulation in the treatment of chorea.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
